Trial Details 198 Total Sites

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

phase

Phase 2

status

Recruiting

enrollment

271

score

42

start date

2018-08-01

last updated

2022-01-11

biomarkers
New York City, New York
facility
Memorial Sloan Kettering Cancer Center
facility
NYP/Weill Cornell Medical Center
2 facilities
Recruiting
Los Angeles, California
facility
Cedars Sinai Medical Center
1 facility
Recruiting
Phoenix, Arizona
facility
Cancer Center at Saint Joseph's
1 facility
Recruiting
Dallas, Texas
facility
Parkland Memorial Hospital
facility
UT Southwestern/Simmons Cancer Center-Dallas
2 facilities
Recruiting
Columbus, Ohio
facility
Ohio State University Comprehensive Cancer Center
1 facility
Recruiting
Fort Worth, Texas
facility
UT Southwestern/Simmons Cancer Center-Fort Worth
1 facility
Recruiting
Denver, Colorado
facility
Porter Adventist Hospital
1 facility
Recruiting
Detroit, Michigan
facility
Ascension Saint John Hospital
1 facility
Recruiting
Oklahoma City, Oklahoma
facility
University of Oklahoma Health Sciences Center
facility
Mercy Hospital Oklahoma City
2 facilities
Recruiting
Sacramento, California
facility
University of California Davis Comprehensive Cancer Center
1 facility
Recruiting
Colorado Springs, Colorado
facility
Rocky Mountain Cancer Centers-Penrose
facility
Penrose-Saint Francis Healthcare
+1 more facilities
3 facilities
Recruiting
Omaha, Nebraska
facility
Alegent Health Immanuel Medical Center
facility
Creighton University Medical Center
+2 more facilities
4 facilities
Recruiting